Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04706741 | A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis | PHASE2 | COMPLETED | 7 | — | — | Jan 6, 2022 | Nov 14, 2022 | Feb 12, 2024 | 4 | United States |
Complete Response is defined as Yes/No by visit by meeting at least 1 of the following criteria in at least one eye: 1. Inflammatory, chorioretinal and/or inflammatory retinal vascular lesions - No such active lesions; all prior lesions appear inactive 2. ACC Count - Trace or absent (0.5+ or 0) 3. Vitreous Haze - Trace or absent (0.5+ or 0)
| Arm | Type | Description |
|---|---|---|
| Izokibep and maintenance corticosteroid dose | EXPERIMENTAL | Izokibep+ Prednisolon/Prednisone |
| Name | Type | Description |
|---|---|---|
| Izokibep | DRUG | Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously |
| Prednisone/Prednisolone | DRUG | Background Corticosteroid |
Inclusion Criteria: 1. ≥18 years of age at SCR 2. Previously documented medical history with diagnosed unilateral or bilateral NIIPPU 3. Active disease at BL defined by the presence of at least 1 of the following criteria in at least one eye despite treatment with stable doses of corticosteroids fo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Roivant Sciences Ltd. | ROIV | 1 | PHASE3 | Brepocitinib |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Baricitinib, Adalimumab |
| ANI Pharmaceuticals, Inc. | ANIP | 1 | PHASE3 | Yutiq Drug |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN7041 |
| TScan Therapeutics, Inc. | TCRX | 1 | — | Undisclosed |